Causal Association in Pharmacovigilance and Pharmacoepidemiology

The methods used for the evaluation of drug safety signals (including major signals leading to withdrawal of products from the market) are inconsistent and sometimes of poor quality. While the assessment of the safety of medicines needs to consider specific issues such as drug interactions and variation in compliance, the general principles, which are used to study environmental hazards, can be applied for this purpose. The criteria proposed by Sir Austin Bradford-Hill more than 35 years ago for attributing disease causation to environmental factors have been used widely in epidemiology, are applicable to pharmacovigilance and pharmacoepidemiology.The Austin Bradford-Hill criteria include strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experimental evidence and analogy. The paper reviews each of these criteria with emphasis on pharmacovigilance and pharmacoepidemiology and with some examples. The application of the Austin Bradford-Hill criteria to the evaluation of causal association in pharmacovigilance and pharmacoepidemiology is very useful. However, it requires understanding of the limitations of the data, such as, under-reporting, poor quality of information from third parties and misclassification. Further work is required to develop strategies to handle these limitations.

[1]  P. Hannaford Cardiovascular Events Associated With Different Combined Oral Contraceptives , 2000, Drug safety.

[2]  D. Bull,et al.  Childhood leukaemia and intramuscular vitamin K: findings from a case-control study , 1996, BMJ.

[3]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[4]  J. Dixon Hormone replacement therapy and the breast , 2001, BMJ : British Medical Journal.

[5]  J. Golding,et al.  Childhood cancer, intramuscular vitamin K, and pethidine given during labour. , 1992, BMJ.

[6]  R. Mann,et al.  Safety of Long‐Term Lamotrigine in Epilepsy , 1997, Epilepsia.

[7]  R. Stern,et al.  Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children , 1999, Epilepsia.

[8]  W. Inman,et al.  ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in Prescription-Event Monitoring , 1996, European Journal of Clinical Pharmacology.

[9]  P. Wright Untoward effects associated with practolol administration: oculomucocutaneous syndrome. , 1975, British medical journal.

[10]  I. Mainie,et al.  Seizures after buproprion overdose , 2001, The Lancet.

[11]  A. Crozier,et al.  Alcohol consumption and mortality: is wine different from other alcoholic beverages? , 2001, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[12]  W. Inman,et al.  Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs , 1970, British medical journal.

[13]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.